Jacob Johnson
Stock Analyst at Stephens & Co.
(3.60)
# 598
Out of 4,829 analysts
77
Total ratings
45.76%
Success rate
7.26%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $233.10 | +2.96% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $5.73 | +4.71% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.98 | -14.04% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $28.30 | +112.01% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $200.83 | +56.85% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $432.59 | +57.19% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $133.72 | +27.13% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $7.06 | -29.18% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.27 | +384.58% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $23.66 | +60.61% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $7.15 | +137.76% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.35 | +85.19% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $53.90 | +61.41% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $219.46 | +77.71% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $8.51 | +111.52% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.63 | +128.14% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $23.89 | +21.39% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $106.38 | +22.20% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $143.08 | +163.49% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $233.10
Upside: +2.96%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.73
Upside: +4.71%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.98
Upside: -14.04%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $28.30
Upside: +112.01%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $200.83
Upside: +56.85%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $432.59
Upside: +57.19%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $133.72
Upside: +27.13%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $7.06
Upside: -29.18%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.27
Upside: +384.58%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $23.66
Upside: +60.61%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $7.15
Upside: +137.76%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.35
Upside: +85.19%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $53.90
Upside: +61.41%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $219.46
Upside: +77.71%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $8.51
Upside: +111.52%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.63
Upside: +128.14%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $23.89
Upside: +21.39%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $106.38
Upside: +22.20%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $143.08
Upside: +163.49%